MaxCyte, Inc. announced a strategic platform license agreement with TG Therapeutics, a biopharmaceutical company specializing in treatments for B-cell diseases. Under this agreement, TG Therapeutics ...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc (MXCT)., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
LAS VEGAS--(BUSINESS WIRE)-- Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results